Lung disease is the major source of morbidity and mortality in cystic fibrosis (CF), a recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene. Allelic variation in *CFTR* does not explain the wide variation in severity of lung disease^[@R1]^ however studies of twins and siblings demonstrate substantial heritability underlying differences in lung function measures in CF patients (*h*^2^ \> 0.5)^[@R2]^. Candidate gene studies have produced conflicting results, with only a few large scale replications accounting for a small proportion of heritable variation in CF lung function^[@R3],[@R4]^. Identification of other genetic modifiers could identify potential mechanisms for variation in lung function in CF, as well as for common diseases such as chronic obstructive pulmonary disease (COPD), and suggest new targets for intervention.

Whole-genome methods provide an attractive approach to identify modifier loci of Mendelian disorders. However CF presents numerous challenges, such as: (1) collecting multiple years of lung function measures to accurately classify lung disease severity; (2) selecting the appropriate study design to identify common and rare variants; (3) accruing sufficient sample sizes, and (4) accounting for potential interaction between *CFTR* and modifier loci. To overcome these challenges, we formed a North American CF Gene Modifier Consortium to identify modifiers of lung disease severity and other phenotypes. For lung disease in CF, the forced expiratory volume in 1 second (FEV~1~) is the most clinically useful measure of lung disease severity and is a well-established predictor of survival^[@R5],[@R6]^. However, comparison of FEV~1~ measures across a broad age range of CF patients is confounded by decline with age and mortality attrition. To account for these confounders, the Consortium developed a quantitative lung disease phenotype based on multiple measures of FEV~1~ over 3 years^[@R7]^ that displays robust genetic influence (*h*^2^ = 0.51)^[@R8]^.

The Consortium is composed of three samples of CF patients recruited using different study designs. The Genetic Modifier Study (GMS) consists of unrelated patients homozygous for the common CF allele *F508del* (HGVS nomenclature: *p.Phe508del*), recruited from extremes of lung function^[@R9]^. The Canadian Consortium for Genetic Studies (CGS) enrolled unrelated patients having pancreatic insufficiency from a population-based sample^[@R10]^. The CF Twin and Sibling Study (TSS) recruited families where two or more surviving children have CF^[@R2]^. The GMS and CGS were designed for association analysis, while the TSS was designed for both linkage and association, providing an opportunity to detect rarer variants or poorly tagged loci.

As many current Genome Wide Association Studies (GWASs) employ sample sizes that are several-fold larger than available for the CF population, we sought to maximize power by (1) testing association using combined data from GMS and CGS, followed by replication using the association evidence from TSS, and (2) testing linkage using the TSS, followed by SNP association testing in linked regions in the unrelated patients in GMS and CGS. We also restricted analysis to patients bearing two severe loss-of-function CFTR alleles and a subset of these patients that had identical *CFTR* genotypes (homozygosity for *F508del*).

RESULTS {#S1}
=======

Genome-wide association analysis of lung disease severity in CF {#S2}
---------------------------------------------------------------

A total of 3,467 CF patients are represented in three study designs ([Table 1](#T1){ref-type="table"}, [Supplementary Note](#SD2){ref-type="supplementary-material"}). Patients in the GMS and 60% of the patients in the CGS and TSS are *F508del* homozygotes (*F508del/F508del*), while the remainder has other severe exocrine pancreatic *CFTR* genotypes^[@R2],[@R9],[@R10]^. The three samples showed consistent distributions of the lung disease phenotype, with the mid-range under-represented in GMS due to the extremes-of-phenotype design ([Figure 1](#F1){ref-type="fig"}). Patients were contemporaneously genotyped using the Illumina 610-Quad array® in a single facility with stringent quality control (Online Methods). Association scans for the GMS and CGS used an additive model adjusted for sex and principal components as described^[@R11]^. Results were combined using a directional meta-analysis approach for (1) GMS and CGS, *n*=2,494 and (2) GMS and CGS *F508del/F508del, n*=1,978 (power analysis shown in [Supplementary Figure 1](#SD2){ref-type="supplementary-material"}).

The combined GMS and CGS analysis identified seven regions with suggestive association (*P* ≤ 1/570,725 = 1.75 × 10^-6^) ([Figure 2](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}). Restricting analysis to *F508del/F508del* patients, the *EHF-APIP* region on 11p13 achieved genome-wide significance at rs12793173 (*P*=3.34 × 10^-8^, explaining 1.0% of the phenotype variation in GMS, 2.2% in CGS *F508del/F508del*). We verified the significance by permutation analysis and by developing an alternative conditional likelihood approach which acknowledged the GMS extremes of phenotype (Online Methods, [Supplementary Figure 2](#SD2){ref-type="supplementary-material"}). With the inclusion of CF-relevant covariates (sex, BMI and previously associated genes), association for rs12793173 was even stronger (*P*= 9.42 × 10^-9^ for GMS and CGS *F508del/F508del*; [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). Two purported modifiers of CF lung disease, *TGFB1* and *IFRD1*, did not achieve genome-wide significance. *TGFB1* did, however, achieve *P*-values in the range of 10^-3^ to 10^-4^ in the GMS sample, depending on additional covariates ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}).

The SNPs in the significant region and the six suggestive regions in GMS and CGS were evaluated for association in TSS using Merlin^[@R12]^, while accounting for family structure. To be consistent with the GMS and CGS allelic effect, each replication test was one-sided, with the TSS sample (all or *F508del/F508del* patients) for each suggestive SNP chosen to be consistent with the GMS and CGS sample set providing maximum significance. Covariates for sex and four principal components^[@R11]^ were included for TSS. The SNP attaining genome-wide significance in GMS and CGS (rs12793173, *F508del/F508del*) demonstrated significant association in the TSS *F508del/F508del* sample (*P*=0.006; Bonferroni corrected *P* = 0.041 for the seven replication tests; [Table 2](#T2){ref-type="table"}). Two of the suggestive SNPs provided modest evidence in TSS: rs9268905 near *HLA-DRA* (*P*=0.032) and rs1403543 near *AGTR2* (*P*=0.053), with neither significant after correcting for the seven replication tests.

We next performed a joint analysis, shown to be more powerful than testing followed by replication^[@R13]^, using a weighted meta-analysis procedure (Online Methods). Using all patients, rs12793173 attained genome-wide significance (*P*=1.12 × 10^-8^). For this patient set, rs568529, a SNP in high LD (*r*^2^ \> 0.9) with rs12793173, achieved slightly greater significance (*P*=9.75 × 10^-9^). As in the earlier analysis, restricting to *F508del/F508del* patients increased the significance of *EHF-APIP* (*P*=1.49 × 10^-9^ for rs12793173 ([Table 2](#T2){ref-type="table"}), *P*=8.28 × 10^-10^ for rs568529). In the HLA class II region, a SNP (rs2395185, \~1kb from the suggestive SNP rs9268905 identified from GMS and CGS) approached genome-wide significance using all patients (*P*=9.02 × 10^-8^; [Supplementary Figure 3](#SD2){ref-type="supplementary-material"}). SNPs in *AGTR2* remained suggestive for all patients (rs5952206, *P*=1.25 × 10^-7^) and for *F508del/F508del* patients (rs7060450, *P*=3.67 × 10^-7^).

[Figure 3](#F3){ref-type="fig"} shows the GMS and CGS results for an 800kb interval including *EHF-APIP*. The minimum *P*-value appears in an intergenic region 3' to both *EHF* and *APIP*. A second peak at rs286873 (*P*=5.62 × 10^-7^) near *EHF* exhibited low linkage disequilibrium (*r*^2^ \< 0.2) with the primary SNP ([Figure 3](#F3){ref-type="fig"}). After conditioning on the primary finding, rs286873 had regional statistical significance (rs12793173; corrected *P*=0.0029), suggesting additional regional genetic variants ([Supplementary Figure 4](#SD2){ref-type="supplementary-material"}). We repeated the testing after MACH imputation^[@R14]^. The imputed SNPs in the region identified the same *EHF/APIP* interval, with minimum *P*=1.45 × 10^-8^, at rs535719, at a position 19kb closer to *APIP* than rs12793173. None of the imputed SNPs produced substantially improved association evidence ([Supplementary Figure 5](#SD2){ref-type="supplementary-material"}). Neither total copy number nor allele-specific copy number (Online Methods) models met genome-wide significance (illustrative Manhattan plot in [Supplementary Figure 6](#SD2){ref-type="supplementary-material"}). Finally, after sequencing the exonic regions of *EHF* and *APIP* in 48 patients with mild pulmonary disease and 48 patients with severe pulmonary disease from the GMS, no additional genetic variation was found that offered insight into putative modifying roles (data not shown).

Linkage of lung disease severity in CF to chromosome 20q13.2 {#S3}
------------------------------------------------------------

Linkage analysis revealed a genome-wide significant multipoint LOD score of 5.03 at rs4811626, located at 53.81 Mb (\~85cM) on chromosome 20q13.2 (nominal *P*=7.9 × 10^-7^ ; genome-wide^[@R15]^ *P*=2.3 × 10^-3^; [Figure 4](#F4){ref-type="fig"}). Another, but more modest linkage signal was on chromosome 1p22.21, with multipoint LOD score of 2.48 for rs941031at 91.07 Mb (119 cM). Inclusion of BMI-Z, an important covariate of CF lung function ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}), increased the LOD score for the linkage peak on 20q13.2 to 5.72 (genome-wide *P*=5.05 × 10^-4^ at rs4811645 which is 0.07cM (0.13Mb) from rs4811626; [Figure 5](#F5){ref-type="fig"}) while linkage on chromosome 1p22.21 decreased to LOD 1.67. Thus, anthropometric measures are not major contributors to the linkage on 20q13.2 but may be playing a role on 1p22.21. We estimated that the QTL at 20q13.2 is approaching 50% of the variation in lung function in the CF sibling pairs ([Supplementary Figure 7](#SD2){ref-type="supplementary-material"}); however, this estimate is highly likely to be biased upward due to winner's curse^[@R16]^.

A region of 1.31 Mb on 20q13.2, demarcated by 1 LOD unit below the maximum (when BMI-Z was used as a covariate), was analyzed for association in the combined GMS and CGS samples. A 16kb cluster of SNPs in high LD (rs6092179, rs6024437, rs8125625, rs6024454 and rs6024460; *r*^2^ \> 0.8) located \~200kb from *CBLN4* generated the lowest *P*-values in the combined GMS and CGS *F508del/F508del* samples ([Figure 5](#F5){ref-type="fig"}). The SNP with the lowest *P*-value (rs6024460; *P*=1.34 × 10^-4^) reached regional significance (corrected *P* = 0.041). Association in the TSS identified a SNP (rs6069437) with marginal association (uncorrected *P* = 0.014) that displays weak LD with the GMS and CGS cluster of SNPs. Imputation did not identify any SNPs exhibiting a lower *P* value for association than rs6024460 ([Supplementary Figure 8](#SD2){ref-type="supplementary-material"}).

A combined false discovery rate approach corroborates genome-wide significance of loci on chromosomes 11 and 20 {#S4}
---------------------------------------------------------------------------------------------------------------

To evaluate association and linkage in a single framework, linkage information was used to reprioritize genome-wide association using extensions of the false discovery rate (FDR)^[@R17]^ via the stratified FDR (SFDR)^[@R18]^ and weighted FDR (WFDR)^[@R19]^. We (1) obtained linkage-weighted *q*-values representing the combined evidence at each SNP, and (2) re-ranked GWAS results by linkage-weighted *q*-values (see Online Methods). Results are presented from the WFDR; results were confirmed using the SFDR (data not shown). SNPs with *q*-values less than 0.05 were declared to be genome-wide significant ([Table 3](#T3){ref-type="table"}). SNPs in the *EHF-APIP* region on chromosome 11 are highly significant (low *q*-values), because of the strong association ([Table 3](#T3){ref-type="table"}). After accounting for linkage, the *q*-values for SNPs under the linkage peak on chromosome 20 are considerably decreased. The results presented in [Table 3](#T3){ref-type="table"} illustrate that the linked SNPs on chromosome 20 are now top ranked genome-wide, while they were ranked 154^th^ or lower, prior to incorporating the linkage information. The top-ranked SNP by the WFDR analysis was rs6092179 at 53.81 Mb on chr 20 (WFDR q-value=0.015, [Table 3](#T3){ref-type="table"}). SNP rs6092179 is within an LD block containing 4 other SNPs (rs6024437, rs8125625, rs6024454 and rs6024460), all demonstrating association with CF lung function and *q*-value \<0.05. A rank-based *q*-value Manhattan plot demonstrates that chromosome 11 and chromosome 20 both attain genome-wide significance ([Supplementary Figure 9](#SD2){ref-type="supplementary-material"}).

DISCUSSION {#S5}
==========

We identified two new loci containing genetic variants contributing to variation in lung function in CF patients. The success of this project reflected: 1) coordinated analysis of three independent samples of the CF population (representing \~15% of all patients in North America) where each study subject was characterized by the same quantitative measure of lung function; 2) simultaneous genotyping of samples using a single platform which allowed for data cleaning using relatedness assessments and removal of poor quality genotypes based on parent to child transmission predictions; 3) analyzing for loci with small effect sizes using association, and loci of major effect (even in the presence of substantial allelic heterogeneity) using linkage. Moreover, we garnered increased power from an extreme of phenotype sample, while a population-based sample allowed for the development of a phenotype with external validity.

The association at chr11p13 is in an intergenic region 3' to *APIP* and *EHF* with regulatory features including: i) significant conservation across species, ii) open chromatin (DNAase hypersensitivity and FAIRE-Seq), and iii) DNAase hypersensitive patterns suggesting cell-type-specificity (<http://genome.ucsc.edu>). The UCLA Gene Expression Tool (UGET, <http://genome.ucla.edu/~jdong/GeneCorr.html>)^[@R20],[@R21]^ indicates correlation of expression of nearby genes, including strong correlation of *EHF* to *ELF5*, both epithelial-specific transcription factors; *APIP* to *PDHX*, which have the same promoter region; and *EHF* to *APIP. APIP* (Apaf-1-interacting protein) is known to inhibit apoptosis by binding to APAF-1, an important activator of caspase-9^[@R22],\ [@R23]^ and by APAF-1 independent activation of AKT and ERK1/2^[@R24]^. *EHF* is a member of epithelial-specific-Ets transcription factors that share a conserved Ets domain^[@R25]-[@R27]^. EHF can be induced in bronchial epithelial cells, smooth muscle cells and fibroblasts^[@R28],[@R29]^, leading to transcriptional repression of a subset of *ETS/AP-1*-responsive genes activated by MAP-kinase pathways^[@R26],[@R28]^, and in airway it may serve as an important regulator of differentiation under conditions of stress and inflammation^[@R26],[@R27]^. Both genes show evidence of robust expression in lung and trachea, with *APIP* showing ubiquitous expression across tissues and *EHF* showing highest expression in trachea (<http://www.ncbi.nlm.nih.gov/UniGene> and <http://www.ncbi.nlm.nig.gov/geo>)^[@R30]^. Interestingly, cis-eQTL signatures for *APIP* are reported for lymphocytes and monocytes (eqtl.uchicago.edu). Comparing the eQTLs to the direction of phenotype-genotype association suggests that increased expression of *APIP* may be associated with decreased lung function, implying that inhibition of apoptosis worsens CF lung disease. This hypothesis is consistent with the emerging concepts that delayed neutrophil clearance, due to reduced apoptosis in neutrophils in the airways of CF patients, could lead to a hyperinflammatory state and more severe lung disease ^[@R31],[@R32]^ and that inhibition of apoptosis contributes to goblet cell metaplasia, a central feature in CF airway pathophysiology^[@R33]^.

All 5 genes within the 1 LOD support interval in the chromosome 20 linkage region ([Figure 5](#F5){ref-type="fig"}) are expressed in either fetal or adult lung or in bronchial epithelial cells (<http://genome.ucsc.edu/>). The 16kb cluster of SNPs associated with lung function in the GMS and CGS samples is located \~200kb to 500 kb centromeric to the five genes. None of the SNPs lies within a segment of open chromatin identified in the 16kb region in Normal Human Bronchial Epithelia cells (<http://genome.ucsc.edu>). Neither eQTL in lymphocytes (eqtl.uchicago.edu), miRNA (<http://www.mirbase.org>) nor DNaseI hypersensitive sites in Small Airway Epithelial cells map to the 16kb region. However, this does not exclude the possibility that the associated region regulates expression of any of the five genes or more distant genes. Among the five genes, *MC3R* has been implicated in weight maintenance and regulation of energy balance in animals and humans^[@R34]-[@R36]^. Variation in resting energy expenditure has been correlated with lung function measurements, lung tissue damage and lung disease exacerbation in CF patients ^[@R37],[@R38]^. *MC3R* has also been implicated as a modulator of neutrophil accumulation in a murine model of lung inflammation^[@R39]^, a key feature of CF lung disease, as noted above. Other genes of interest within the linkage peak encode Crk-associated substrate scaffolding (CASS) 4 (*CASS4/HEPL*), a relative of proteins implicated in cell attachment, migration establishing polarity, invasion and phagocytosis of bacterial pathogens^[@R40]^ and Aurora kinase A (*AURKA*) which been shown to interact with Hef1/NEDD9, a member of the CASS family that mediates cytokinesis in late mitosis and facilitates disassembly of primary cilia^[@R41]^.

Twin studies in adults demonstrate that FEV~1~ is under strong genetic influence^[@R42],[@R43]^, and at least three loci (*GSTCD, TNS1* and *HTR4*) have been reproducibly associated with this measure^[@R44]-[@R46]^. Multiple replicated loci have also been associated with variation in the FEV~1~/FVC ratio^[@R45],[@R46]^ and at least two of these loci (*HHIP* and *FAM13*) show reproducible association with COPD^[@R44],[@R47],[@R48]^. While the lung phenotype used here was based on FEV~1~, none of the above loci coincides with the regions identified in this study and neither of the loci identified here occur within the top 2000 associations for FEV~1~ or FEV~1~/FVC^[@R45],[@R46]^.

Common variation in the *EHF/APIP* region is estimated to alter the lung function measure in the GMS and CGS *F508del/F508del* patients by \~0.2 units of the quantitative lung disease phenotype per allele ([Table 2](#T2){ref-type="table"}). Translated into more familiar clinical terms, the 0.2 unit difference is approximately equivalent to a mean difference in FEV1 percent predicted of 5.1 ± 1.9, corresponding to a mean difference in FEV~1~ of 254 ± 86mL in patients over 18 years of age (Online Methods). The QTL on chromosome 20 may account for a sizeable fraction of lung function variation in CF. Using simulations described by Blangero and colleagues^[@R16]^, we estimate that this locus accounts for a maximum of 46% and a minimum of 4% of the variance in the CF siblings (Online Methods).

In summary, our association and linkage approach provided complementary findings with the identification of two significant loci harboring genes of biologic relevance for CF. Of particular note for modifier searches in other monogenic diseases is the potential importance of minimizing variation in the causative gene. When we confined association analysis to patients with identical CFTR genotypes (i.e. *F508del/F508del*), one of the 7 suggestive loci achieved genome-wide significance, despite the reduction in sample size due to the exclusion of 38% of subjects in the CGS sample with other *CFTR* genotypes. The remaining suggestive loci contain biologically intriguing candidate modifiers that will be evaluated in future studies. Finally, the identification of genetic loci that modify lung function in CF, should provide new insight leading to the development of novel therapies for this devastating condition.

ONLINE METHODS {#S6}
==============

Genotyping and quality control {#S7}
------------------------------

DNA from whole blood or transformed lymphocytes was hybridized to the Illumina 610-Quad ® platform at Genome Quebec (McGill University and Genome Quebec Innovation Centre,) using the 96-well plates with CEPH and one replicate control per plate. Illumina BeadStudio® was used to call genotype, and identity confirmed by Sequenom® fingerprinting. SNPs were removed if they were monomorphic, missing \> 10% calls or with \>1% Mendelian error in TSS trios. Finally, 570,725 autosomal and X-chromosome SNPs were selected, as well as 158 chromosome Y SNPs and 138 mitochondrial SNPs. Duplicate discordance was 0.004% in GMS, and similar for the other studies.

Sample exclusions included: initial call rate below 98%, unexpected close relatives or duplicate enrollments, unresolved sex mismatches, aneuploidy or outlying heterozygosity (\> 5 standard deviations from the mean of 31.6%). Overlapping from 542 Illumina GoldenGate ® SNPs in GMS revealed platform discordance of 0.07%. Families with \>5% Mendelian errors were excluded. Twenty-eight patient samples were excluded (GMS6; CGS 17, TSS 5) due to genotyping failure or artifacts, two GMS samples excluded due to outlying ancestry (by PC analysis), and eight GMS samples excluded for \> second degree relation with other samples. Reported findings were verified using Illumina GenomeStudio V1.0.2® module V1.0.10 and manually-assisted calling.

Association testing {#S8}
-------------------

Regressions for the lung phenotype were performed separately for GMS, all CGS, and CGS *F508del/F508del* using an additive model in PLINK v. 1.07 ^[@R49]^, adjusted for sex and genotype principal components (PCs)^[@R11]^. Using the PLINK z-statistics for GMS and CGS, the standard meta-analysis z-statistic^[@R50]^ was *z* = *w~GMS~z~GMS~* + *w~CGS~z~CGS~*, with weights inversely proportional to standard errors, and common reference alleles for directional consistency. "Suggestive" association used the approximate threshold 1/(number of SNPs)=1/570,725=1.75 × 10^-6^, and significant association the Bonferroni threshold *P* \< 0.05/570,725 = 8.76 × 10^-8^. For males, X-chromosome genotypes followed PLINK defaults (0 or 1 minor alleles; alternative coding resulted in no qualitative changes).

Permutations of genotypes relative to phenotypes and covariates (1,000) were used to refine the thresholds. From this pool of permutations, 10,000 permuted meta-analyses were computed. The obtained significance thresholds for a genome-wide error 0.05 were *P* = 1.07 × 10^-7^ (GMS and CGS) and *P* = 1.05 × 10^-7^ (GMS and CGS *F508del/F508del*). Consequently, *P*\< 5 × 10^-8^ achieves false positive error control at genome-wide α\<0.05, even correcting for two separate GWAS analyses. Regional multiple-comparisons correction (after highlighting a region) used the Bonferroni correction for the regional SNPs.

TSS association analysis was performed in 973 CF siblings and for the 557-patient *F508del/F508del* subset using the Merlin variance-components additive model framework^[@R12]^, corrected for linkage, family structure, sex, and 4 PCs. Missing genotypes (0.125%) were inferred to increase power^[@R51]^. Joint analyses of GMS, CGS and TSS used the meta-analysis approach described above.

A combined conditional likelihood approach {#S9}
------------------------------------------

We devised a novel approach using the assumption that CGS represents a random population sample, whereas GMS was conditional on the observed phenotypes. Letting *g* be the number of SNP minor alleles, the phenotypes *y* were pre-adjusted for sex and the study-specific PCs. We assumed an additive model *y* = *β~0~ + β~1~g + ε, ε \~ N* (0, *σ*^2^). The full likelihood conditioned on GMS sampling was $\begin{array}{lll}
L & = & {p{({g_{\mathit{CGS}},y_{\mathit{CGS}};\beta_{0},\beta_{1},\sigma^{2}})}\ p{({g_{\mathit{GMS}} \mid y_{GMS};\beta_{0},\beta_{1},\sigma^{2}})}} \\
 & = & {p{(g_{\mathit{CGS}})}\ p{(g_{\mathit{GMS}})}\ p{({y_{\mathit{CGS}} \mid g_{\mathit{CGS}};\beta_{0},\beta_{1},\sigma^{2}})}\ p{({y_{\mathit{GMS}} \mid g_{\mathit{CGS}};\beta_{0},\beta_{1},\sigma^{2}})}/p{({y_{\mathit{GMS}};\beta_{0},\beta_{1},\sigma^{2}})}} \\
\end{array}$ where $p{({y_{\mathit{GMS}};\beta_{0},\beta_{1},\sigma^{2}})} = \underset{j = 0}{\overset{2}{\sum}}{p{({g_{\mathit{GMS}} = j})}\ p{({y_{\mathit{GMS}} \mid g_{\mathit{GMS}} = j;\beta_{0},\beta_{1},\sigma^{2}})}}$. Finally, we computed the SNP-specific statistic 2 × (log-likelihood ratio), with *β*~1~ = 0 as the null and compared to 2 $\chi_{1}^{2}$. The approach assumes the effect sizes are the same in GMS and CGS, which is true under the null.

Power Analyses {#S10}
--------------

Power analyses for the combination of GMS and CGS assumed an additive genetic model, with effect *β*~1~ on the average phenotype for each minor allele. The results for GMS and CGS *F508del/F508del* are in [Supplementary Figure 1](#SD2){ref-type="supplementary-material"}. For each simulation the weighted meta-analysis *P*-values were compared to 5 × 10^-8^.

Genotype imputation {#S11}
-------------------

MACH (autosomes, <http://www.sph.umich.edu/csg/abecasis/mach/>) and IMPUTE (chromosome X, <http://mathgen.stats.ox.ac.uk/impute/impute.html>) imputation was conducted for 1162 GMS patients, 1,254 self-reported CGS "Caucasian" patients and 60 CEU reference samples from HapMap I/II. Some of these individuals were later used for TSS, and association analyses considered only unique subsets in GMS and CGS, respectively ([Table 1](#T1){ref-type="table"}). Imputation yielded data for \~2,544,000 autosomal and \~65,000 chromosome X SNPs.

Copy-number analysis {#S12}
--------------------

Copy number variants (CNVs) were detected using pennCNV (2008Nov19 version)^[@R52]^ and genoCNV (version 1.08)^[@R53]^ using default parameters in 1103 GMS and 1301 CGS samples. CNVs with fewer than 5 probes or showing \<1% variation were used, resulting in 3,008/4,868 probes from genoCNV/pennCNV in GMS and 3015/4663 probes for genoCNV /pennCNV in CGS. Genotype PCs were used to control stratification.

Linkage Marker Selection {#S13}
------------------------

19,566 SNPs were selected from the Illumina platform with minor allele frequency \>0.4 and *r^2^* \<0.01 between adjacent SNPs, using Merlin^[@R54]^. HapMap II recombination data were used to integrate genetic and physical map positions. Average inter-marker distance was 0.18 cM, or 0.13 Mbp. Physical positions not appearing in HapMap were estimated assuming uniform recombination between known adjacent SNPs. The average marker information content was \~0.9 (multipoint) and \~0.31 (two-point).

Linkage Analysis {#S14}
----------------

Variance components were estimated in SOLAR (Sequential Oligogenic Linkage Analysis Routines)^[@R55]^, with similar results from Merlin^[@R54]^, using multipoint IBD probabilities obtained from Merlin. LOD scores were computed with and without covariates (sex and average BMI Z-score). Multipoint LODs\>2.0 was considered suggestive and LOD\>3.7 was considered genome-wide significant^[@R15]^.

WFDR and SFDR methods {#S15}
---------------------

Let *P~i~* be the p-value of an association test for SNP *i, i* =1*,...,m*. Converting p-values to *q*-values^[@R56]^ controls the FDR. SNPs with *q*-values less than the FDR threshold value (e.g. *γ* = 0.05) are declared significant. The expected proportion of false positives among all the positives is then controlled at level *γ*. Note that ranking SNPs by *P*-value or *q*-value are equivalent.

Let *Z~i~* be the linkage score of SNP *i* obtained from a GWL study. For the SFDR method, *m* SNPs are divided into *K* disjoint strata based on the prior linkage information^[@R57]^. Cconsider *K* = 2 and assign each SNP *i* to stratum 1 (the high priority group) or stratum 2 (the low priority group) according to whether the linkage score *Z~i~* exceeds a threshold *C* (we used *C*=3.3 corresponding to significant linkage^[@R15]^). Q-values are then calculated separately for each stratum of SNPs, achieving FDR control in each stratum (Sun et al., 2006). Ranks of the GWAS SNPs are determined by the q-values with the original association p-values used to break any q-value ties.

WFDR calculates a weighting factor *W~i~* for each SNP *i* with weights subject to two constraints: *W~i~* ≥ 0\_ and *W̄* = Σ~*i*~ *W~i~ /m* = 1. The weight *W~i~* is proportional to the linkage signal *Z~i~* for SNP *i* (e.g.*W~i~* exp(*B · Z~i~*) / *ν, ν* = Σ~i~ exp(*B · Z~i~*)/*m*,, and *B*=1) (Roeder et al., 2006), and the FDR procedure is applied to the set of weight-adjusted p-values, *P~i~/W~i~, i* =1,...,*m*. We use B=2 in the present analysis. The WFDR and SFDR were implemented in a perl program called *SFDR*, available at <http://www.utstat.toronto.edu/sun/Software/SFDR/index.html>.

Phenotype variation attributable to association and to linkage {#S16}
--------------------------------------------------------------

The proportion of variation due to each SNP was measured as the change in regression sums of squares vs. the smaller model with the SNP removed^[@R58]^. Using the genome-scan threshold of *P*=5 ×10^-8^ and minimum *P*=3.34 × 10^-8^ in the chromosome 11p13 region for GMS and CGS *F508del/F508del* patients, we estimate a 57.4% reduction in effect size compared to the nominal result. Using the joint analysis based on GMS, CGS *F508del/F508del* and TSS *F508del/F508del* patients, the observed minimum *P*=8.28 × 10^-8^ results in \~ 28.0% reduction of the effect size. Using the rough parallel to explained variation in the trait, the estimated explained variation for 11p13 remains 1%-2%. For a linkage study of comparable size (*n*=500 sibling pairs), with a phenotype heritability of 0.5, the bias attributed to the winner's curse varies from approximately 0.46 down to zero as the true (unmeasured) heritability attributable to the QTL increases^[@R16]^. While not possible to quantify the magnitude of this bias in this single study, these calculations provide an upper bound on the bias of 0.38 to 0.46 and a lower bound of 0.04 to 0.12.

Estimation of changes in the CF lung phenotype upon FEV1 %predicted and airway flow {#S17}
-----------------------------------------------------------------------------------

Using 973 TSS individuals, a hypothetical quantity of 0.2 was added to each individual's lung phenotype, to correspond to the effect size observed for the significant association of SNPs near *EHF/APIP*. The average raw FEV1 (in liters) was then back-extrapolated^[@R8]^ and FEV1 percent predicted values were generated using the predictive equations^[@R59],[@R60]^. Height and age adjustments used to calculate the original quantitative lung phenotype were preserved. The average increase (mean ± SD) in FEV~1~ percent predicted corresponding to a 0.2-unit increase of our lung phenotype was 5.09% ± 1.90% \[n = 841; Range: 0.00 -- 14.53%\]. The corresponding average increase in raw FEV1 was 253.5 ± 85.9mL in adult subjects (\>18 years) \[n = 244; Range: 0.0 -- 630.0mL\].
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![Histograms of the Consortium lung phenotype for the three cystic fibrosis studies show similar average phenotypes. The phenotype mean is above zero due to a lower bound placed by the survival correction, as well as cohort effects of improving lung function. (a) The two designs using unrelated individuals. All of the patients in the Genetic Modifier Study (GMS) are *F508del/F508del* at CFTR. These patients were oversampled at extremes of an initial entry phenotype, in order to improve power, and the original severe/mild designations are colored separately. In contrast, the Canadian Consortium for Genetic Studies (CGS) is population based, representing a range of pancreatic insufficient CFTR genotypes. (b) Patients enrolled in the family-based Twin and Sibling Study (TSS) show a similar distribution of the Consortium lung phenotype as the population-based CGS.](nihms291279f1){#F1}

![Genome-wide Manhattan plots for the cystic fibrosis Consortium lung function phenotype, combining the association evidence from GMS and CGS samples across 570,725 SNPs. The black dashed line represents the Bonferroni threshold for genome-wide α=0.05, while the green dashed line is the suggestive association threshold, expected once per genome scan. SNPs are plotted in Mb relative to their position on each chromosome (alternating blue and black) (a) Results from GMS (n=1137, all of whom are *F508del/F508del*) combined with all of the CGS patients (n=1357). Seven regions reach suggestive significance. (b) Results from the combined evidence of GMS (n=1137) and the CGS *F508del/F508del* (n=841). A region on chromosome 11p13 reaches genome-wide significance (*P*=3.34 × 10^-8^).](nihms291279f2){#F2}

![A plot of the association evidence in GMS and CGS *F508del/F508del* in the chromosome 11p13 *EHF/APIP* region (NCBI build 36, LocusZoom viewer). Colors represent HapMap CEU linkage disequilibrium r^2^ with the most significant SNP, rs12793173 (*P*=3.34 × 10^-8^). The secondary peak at rs286873 has relatively low r^2^ with the primary peak.](nihms291279f3){#F3}

![Genome-wide linkage scan for the Consortium lung phenotype of 486 sibling pairs in the family-based TSS, adjusted for sex. A QTL with a genome-wide significant LOD=5.03 was found on 20q13.2. LOD scores with SNPs used in the linkage panel are plotted in cM relative to their position on each chromosome (alternating blue and black).](nihms291279f4){#F4}

![Regional analysis of the QTL on chromosome 20q13.2 **(a)** A detailed chromosome 20 linkage plot for the Consortium lung phenotype in the TSS study, with covariates sex (essentially the same result as for no covariates) and with covariates sex and BMI. **(b)** Association evidence from the GMS and CGS *F508del/F508del* patients, in the 1-LOD support interval provided by TSS. A region centromeric to *CBLN4* and *MC3R* on 20q13.2 shows suggestive evidence of association, with the greatest evidence at rs6024460 (*P*=1.34 × 10^-4^).](nihms291279f5){#F5}

###### 

Characteristics of patients enrolled by the three studies comprising the North American CF Gene Modifier Consortium

                                                         Genetic Modifier Study (GMS)           Canadian Consortium for Genetic Studies (CGS)   Twins & Sibs Study (TSS)                                  
  ------------------------------------------------------ -------------------------------------- ----------------------------------------------- --------------------------------------------------------- ------------
  **Lead Institution(s)**                                Univ. of North Carolina/Case Western   Hosp. Sick Children                             Johns Hopkins                                             
   **Design**                                            Extremes-of-Phenotype Unrelated        Population-Based Unrelated                      Family-Based                                              
   **Type of Evidence**                                  Association                            Association                                     Linkage and association                                   
  **Number of patients**                                 1,137                                  1,357                                           973 [a](#TFN1){ref-type="table-fn"} (486 sibling pairs)   
  Severe (*n* = 406)                                     Mild (*n* = 731)                                                                                                                                 
  **Age**                                                                                                                                                                                                 
   **Mean ± SD (yrs)**                                   15.2 ± 4.6                             27.5 ± 9.8                                      18.5 ± 9.5                                                15.5 ± 7.8
   **Range (yrs)**                                       8-25                                   15-56                                           6-49                                                      6-55
  **Male *n* (%)**                                       194 (47.8%)                            405 (55.4%)                                     734 (54.1%)                                               521 (53.5)
  **Caucasian *n* (%)**[b](#TFN2){ref-type="table-fn"}   1,137 (100.0%)                         1,180 (87.0%)                                   898 (92.3%)                                               
  ***F508del/F508del n* (%)**                            1,137 (100.0%)                         841 (62.0%)                                     557 (57.2%)                                               
  **Pancreatic Exocrine Insufficient *n* (%)**           1,137 (100.0%)                         1,357 (100.0%)                                  973 (100.0%)                                              

420 two-sib families, 20 three-sib families, 1 four-sib family and 69 singletons.

Based on self-identified ancestry and principal components analysis.

###### 

Significant and suggestive association results for GMS and CGS, with replication values for TSS

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP          Chr   Base pair[a](#TFN3){ref-type="table-fn"}   Nearest\     Category[b](#TFN4){ref-type="table-fn"}   Risk\                                   Non-\                                   (Minor\                                GMS\                                   CGS\          CGS\   Analysis with\               *P*-value:\   *P*-value:\   *P*-value:\                          *P*-value:\
                                                                Gene                                                   allele[c](#TFN5){ref-type="table-fn"}   risk\                                   allele)\                               coef.[e](#TFN7){ref-type="table-fn"}   *F508del/*\   All\   max\                         GMS+CGS\      GMS+\         TSS[f](#TFN8){ref-type="table-fn"}   Joint~[g](#TFN9){ref-type="table-fn"}~
                                                                                                                                                               allele[c](#TFN5){ref-type="table-fn"}   Freq.[d](#TFN6){ref-type="table-fn"}                                          *F508del*\    coef   significance                 *F508del/*\   CGS All                                            
                                                                                                                                                                                                                                                                                     coef.                                             *F508del*                                                        
  ------------ ----- ------------------------------------------ ------------ ----------------------------------------- --------------------------------------- --------------------------------------- -------------------------------------- -------------------------------------- ------------- ------ ---------------------------- ------------- ------------- ------------------------------------ ----------------------------------------
  rs12793173   11    34,790,780                                 *APIP/EHF*   Significant                               C                                       T                                       \(C\) 0.24                             0.16                                   0.20          0.12   GMS+CGS *F508del/F508 del*   3.34E-08      1.76E-06      0.006                                1.49E-09

  rs1403543    X     115,216,220                                *AGTR2*      Suggestive                                A                                       G                                       \(G\) 0.49                             0.22                                   0.07          0.11   GMS+CGS All                  1.61E-05      2.58E-07      0.053                                1.71E-06

  rs9268905    6     32,540,055                                 *HLA-DRA*    Suggestive                                C                                       G                                       \(C\) 0.32                             0.16                                   0.10          0.12   GMS+CGS All                  1.42E-05      2.81E-07      0.032                                1.21E-07

  rs4760506    12    91,857,181                                 *EEA1*       Suggestive                                G                                       A                                       \(A\) 0.45                             0.16                                   0.10          0.10   GMS+CGS All                  6.77E-06      8.56E-07      0.594                                9.15E-05

  rs12883884   14    69,586,936                                 *SLC8A3*     Suggestive                                T                                       G                                       \(G\) 0.39                             0.12                                   0.15          0.12   GMS+CGS All                  1.20E-06      9.56E-07      0.223                                7.81E-06

  rs12188164   5     481,236                                    *AHRR*       Suggestive                                A                                       C                                       \(A\) 0.38                             0.08                                   0.12          0.15   GMS+CGS All                  5.92E-04      1.34E-06      0.136                                3.65E-06

  rs11645366   16    60,934,654                                 *CDH8*       Suggestive                                C                                       T                                       \(T\) 0.23                             0.17                                   0.13          0.13   GMS+CGS All                  1.23E-05      1.52E-06      0.182                                7.03E-06
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NCBI build 36.

Significant and suggestive imply *P* ≤(0.05/570725)=8.76 × 10^-8^ or *P* ≤ (1/570725)=1.75 × 10^-6^, respectively, for at least one analysis (GMS+CGS *F508del/F508del* or GMS+CGS All).

Alleles indexed to the forward strand of NCBI build 36; the risk allele is the allele associated with worse lung function.

Minor allele frequencies are listed for all GMS +CGS All. Study-specific MAFs are provided in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}.

Coefficients refer to the average reduction in the Consortium lung phenotype for each copy of the risk allele.

TSS direction-consistent association p-value, for TSS *F508del/F508del* only, or TSS All Patients, selected according to the GMS+CGS result with maximum significance.

Joint meta-analysis P-value for GMS, CGS, and TSS, with selection of patients (*F508del/F508del* only, or All Patients) according to the GMS+CGS result with maximum significance

###### 

Combined association and linkage-weighted FDR *q*-values and genome-wide ranks for SNPs with WFDR q-values genome-wide significant (\< 0.05)

  Chr      SNP             Base Pair      GMS+CGS *F508del/F508del* Association *P* value   FDR *q*-value[a](#TFN10){ref-type="table-fn"}   FDR rank   WFDR *q*-value[b](#TFN11){ref-type="table-fn"}   WFDR rank
  -------- --------------- -------------- ------------------------------------------------- ----------------------------------------------- ---------- ------------------------------------------------ -----------
  **11**   rs93138         9716289        5.08E-06                                          0.0124                                          7          0.0383                                           16
  **11**   rs11032829      34705078       2.29E-06                                          0.008                                           3          0.0277                                           8
  **11**   **rs7924717**   **34732907**   **2.76E-06**                                      **0.008**                                       **1**      **0.0218**                                       **6**
  **11**   rs10466455      34737512       3.86E-07                                          0.0124                                          6          0.0375                                           14
  **11**   rs7929679       34762425       1.47E-06                                          0.008                                           5          0.0282                                           10
  **11**   rs10836312      34767019       1.56E-07                                          0.008                                           2          0.0277                                           7
  **11**   rs525202        34778524       1.34E-07                                          0.008                                           4          0.0277                                           9
  **20**   rs7265042       53790816       1.14E-03                                          0.7852                                          1976       0.0459                                           18
  **20**   rs6098782       53791974       1.84E-03                                          0.7349                                          865        0.0459                                           17
  **20**   rs910668        53794753       1.09E-03                                          0.5029                                          175        0.015                                            2
  **20**   rs6092176       53799109       1.51E-03                                          0.5581                                          255        0.015                                            5
  **20**   **rs6092179**   **53812440**   **1.93E-04**                                      **0.484**                                       **154**    **0.015**                                        **1**
  **20**   rs6024437       53813962       1.61E-04                                          0.7553                                          1116       0.0353                                           13
  **20**   rs8125625       53820352       2.49E-04                                          0.516                                           207        0.015                                            3
  **20**   rs6024454       53826840       2.56E-04                                          0.7615                                          1348       0.0381                                           15
  **20**   rs6024460       53828948       1.34E-04                                          0.7349                                          854        0.0296                                           12
  **20**   rs11907114      53862354       2.79E-03                                          0.554                                           250        0.015                                            4
  **20**   rs1326022       54277432       1.16E-03                                          0.7344                                          824        0.0296                                           11

Benjamini-Hochberg approach based on association *P*-value.

Weighted FDR using combined linkage information and association *P*-values.

Rows in bold indicate the top ranked SNPs before incorporating linkage evidence (rs7924717 on chromosome 11) and after (rs6092179 on chromosome 20)
